GlassScriptPhysician profile
Sayeh Barzin
NPI 1558565572
$11,545.03
in general payments reported to CMS, 2019-2025
37 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,257 · 2020: $1,333 · 2021: $1,593 · 2022: $1,620 · 2023: $1,806 · 2024: $1,492 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,836.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,315.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,209.26 | 2019-2025 | Jardiance, Glyxambi, Tradjenta |
| Lilly USA, LLC | $1,090.58 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $962.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $637.27 | 2019-2025 | Belsomra, Steglatro, Capvaxive |
| Abbott Laboratories | $506.14 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $475.42 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $440.67 | 2019-2022 | |
| Pfizer INC. | $439.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $389.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $344.49 | 2019-2025 | |
| Amgen INC. | $332.39 | 2019-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $217.86 | 2021-2024 | |
| Allergan, INC. | $135.48 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayeh Barzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.